Compare AIV & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIV | LYEL |
|---|---|---|
| Founded | 1975 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.7M | 320.1M |
| IPO Year | 1996 | 2021 |
| Metric | AIV | LYEL |
|---|---|---|
| Price | $2.42 | $11.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $10.00 | ★ $30.60 |
| AVG Volume (30 Days) | ★ 969.2K | 92.9K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 87.41% | N/A |
| EPS Growth | ★ 616.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $138,486,000.00 | $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8,712.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.46 | $11.47 |
| 52 Week High | $8.03 | $45.00 |
| Indicator | AIV | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 26.67 | 35.26 |
| Support Level | N/A | $11.59 |
| Resistance Level | $2.74 | $14.14 |
| Average True Range (ATR) | 0.05 | 0.81 |
| MACD | -0.00 | -0.30 |
| Stochastic Oscillator | 4.55 | 4.37 |
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment, and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development. Operating, and Other. The development segment consists of properties that are under construction or have not achieved stabilization, as well as land held for development. The operating segment includes residential apartments, communities with apartment homes that have achieved a stabilized level of operations. The other segment includes The Benson Hotel, the company's only hotel. The majority of revenue is gained from the Operating Segment.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.